Skip to Content

Ocrevus - Are most insurance carriers approving this medicine ?

Responses (1)

suzanne66 29 May 2017

The FDA has approved Ocrevus (ocrelizumab) for the treatment of adults with primary progressive MS and with relapsing MS.
List cost is $65,000 per year so access will depend on individual insurance plans.
For people who qualify, Genentech plans to offer patient assistance programs through Genentech Access Solutions: (866) 4ACCESS/(866) 422-2377 or free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Similar Questions